• Je něco špatně v tomto záznamu ?

Remote Heart Failure Symptoms Assessment After Myocardial Infarction Identifies Patients at Risk for Death

P. Wohlfahrt, D. Jenča, V. Melenovský, J. Stehlik, JA. Spertus, J. Mrázková, M. Šramko, M. Kotrč, M. Želízko, V. Adámková, J. Piťha, J. Kautzner

. 2024 ; 13 (2) : e032505. [pub] 20240109

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007567

BACKGROUND: Heart failure is a common complication after myocardial infarction (MI) and is associated with increased mortality. Whether remote heart failure symptoms assessment after MI can improve risk stratification is unknown. The authors evaluated the association of the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ) with all-cause mortality after MI. METHODS AND RESULTS: Prospectively collected data from consecutive patients hospitalized for MI at a large tertiary heart center between June 2017 and September 2022 were used. Patients remotely completed the KCCQ 1 month after discharge. A total of 1135 (aged 64±12 years, 26.7% women) of 1721 eligible patients completed the KCCQ. Ranges of KCCQ scores revealed that 30 (2.6%), 114 (10.0%), 274 (24.1%), and 717 (63.2%) had scores <25, 25 to 49, 50 to 74, and ≥75, respectively. During a mean follow-up of 46 months (interquartile range, 29-61), 146 (12.9%) died. In a fully adjusted analysis, KCCQ scores <50 were independently associated with mortality (hazard ratio [HR], 6.05 for KCCQ <25, HR, 2.66 for KCCQ 25-49 versus KCCQ ≥50; both P<0.001). Adding the 30-day KCCQ to clinical risk factors improved risk stratification: change in area under the curve of 2.6 (95% CI, 0.3-5.0), Brier score of -0.6 (95% CI, -1.0 to -0.2), and net reclassification improvement of 0.71 (95% CI, 0.45-1.04). KCCQ items most strongly associated with mortality were walking impairment, leg swelling, and change in symptoms. CONCLUSIONS: Remote evaluation of heart failure symptoms using the KCCQ among patients recently discharged for MI identifies patients at risk for mortality. Whether closer follow-up and targeted therapy can reduce mortality in high-risk patients warrants further study.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007567
003      
CZ-PrNML
005      
20240423160056.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1161/JAHA.123.032505 $2 doi
035    __
$a (PubMed)38193321
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Wohlfahrt, Peter $u Department of Preventive Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic $u First Medical School Charles University Prague Czech Republic $1 https://orcid.org/000000032390526X
245    10
$a Remote Heart Failure Symptoms Assessment After Myocardial Infarction Identifies Patients at Risk for Death / $c P. Wohlfahrt, D. Jenča, V. Melenovský, J. Stehlik, JA. Spertus, J. Mrázková, M. Šramko, M. Kotrč, M. Želízko, V. Adámková, J. Piťha, J. Kautzner
520    9_
$a BACKGROUND: Heart failure is a common complication after myocardial infarction (MI) and is associated with increased mortality. Whether remote heart failure symptoms assessment after MI can improve risk stratification is unknown. The authors evaluated the association of the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ) with all-cause mortality after MI. METHODS AND RESULTS: Prospectively collected data from consecutive patients hospitalized for MI at a large tertiary heart center between June 2017 and September 2022 were used. Patients remotely completed the KCCQ 1 month after discharge. A total of 1135 (aged 64±12 years, 26.7% women) of 1721 eligible patients completed the KCCQ. Ranges of KCCQ scores revealed that 30 (2.6%), 114 (10.0%), 274 (24.1%), and 717 (63.2%) had scores <25, 25 to 49, 50 to 74, and ≥75, respectively. During a mean follow-up of 46 months (interquartile range, 29-61), 146 (12.9%) died. In a fully adjusted analysis, KCCQ scores <50 were independently associated with mortality (hazard ratio [HR], 6.05 for KCCQ <25, HR, 2.66 for KCCQ 25-49 versus KCCQ ≥50; both P<0.001). Adding the 30-day KCCQ to clinical risk factors improved risk stratification: change in area under the curve of 2.6 (95% CI, 0.3-5.0), Brier score of -0.6 (95% CI, -1.0 to -0.2), and net reclassification improvement of 0.71 (95% CI, 0.45-1.04). KCCQ items most strongly associated with mortality were walking impairment, leg swelling, and change in symptoms. CONCLUSIONS: Remote evaluation of heart failure symptoms using the KCCQ among patients recently discharged for MI identifies patients at risk for mortality. Whether closer follow-up and targeted therapy can reduce mortality in high-risk patients warrants further study.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a hospitalizace $7 D006760
650    12
$a srdeční selhání $x terapie $7 D006333
650    12
$a infarkt myokardu $x komplikace $x diagnóza $7 D009203
650    _2
$a propuštění pacienta $7 D010351
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a kvalita života $7 D011788
650    _2
$a zdravotní stav $7 D006304
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jenča, Dominik $u Department of Cardiology Institute for Clinical and Experimental Medicine (IKEM) Prague Czech Republic $u Third Medical School, Charles University Prague Czech Republic $1 https://orcid.org/0000000304328460
700    1_
$a Melenovský, Vojtěch $u Department of Cardiology Institute for Clinical and Experimental Medicine (IKEM) Prague Czech Republic $1 https://orcid.org/0000000189217078 $7 xx0160847
700    1_
$a Stehlik, Josef $u University of Utah School of Medicine Salt Lake City UT USA $1 https://orcid.org/0000000273620513
700    1_
$a Spertus, John A $u University of Missouri Kansas City's Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute Kansas City MO USA $1 https://orcid.org/0000000228392611
700    1_
$a Mrázková, Jolana $u Experimental Medicine Centre Institute for Clinical and Experimental Medicine (IKEM) Prague Czech Republic $1 https://orcid.org/0000000276943107
700    1_
$a Šramko, Marek $u First Medical School Charles University Prague Czech Republic $u Department of Cardiology Institute for Clinical and Experimental Medicine (IKEM) Prague Czech Republic
700    1_
$a Kotrč, Martin $u Department of Cardiology Institute for Clinical and Experimental Medicine (IKEM) Prague Czech Republic $1 https://orcid.org/0000000220680379
700    1_
$a Želízko, Michael $u Department of Cardiology Institute for Clinical and Experimental Medicine (IKEM) Prague Czech Republic
700    1_
$a Adámková, Věra $u Department of Preventive Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic $1 https://orcid.org/0000000186793184 $7 jx20050329003
700    1_
$a Piťha, Jan $u Department of Cardiology Institute for Clinical and Experimental Medicine (IKEM) Prague Czech Republic $1 https://orcid.org/0000000193100067
700    1_
$a Kautzner, Josef $u Department of Cardiology Institute for Clinical and Experimental Medicine (IKEM) Prague Czech Republic $u Medical and Dentistry School Palacký University Olomouc Czech Republic $1 https://orcid.org/0000000216326182 $7 xx0037112
773    0_
$w MED00188127 $t Journal of the American Heart Association $x 2047-9980 $g Roč. 13, č. 2 (2024), s. e032505
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38193321 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160052 $b ABA008
999    __
$a ok $b bmc $g 2081518 $s 1217334
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 13 $c 2 $d e032505 $e 20240109 $i 2047-9980 $m Journal of the American Heart Association $n J Am Heart Assoc $x MED00188127
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace